Enliven Therapeutics, Inc. — Filing identity and reporting period
Important identity discrepancy: The supplied filing is IMARA Inc.’s Form 10-Q for the quarter ended June 30, 2021, not a filing by Enliven Therapeutics, Inc. The summary below describes IMARA’s filing.
IMARA was a clinical-stage biotechnology company developing IMR-687 (tovinontrine), its sole product candidate, for sickle cell disease (SCD) and beta-thalassemia. It had no approved products and no product revenue.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data. The three-month figures are for Q2; six-month figures are year to date.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $10.1 | $7.9 | $17.2 | $13.7 |
| General and administrative expense | $3.1 | $2.4 | $6.3 | $4.0 |
| Net loss | $(13.2) | $(10.2) | $(23.4) | $(17.4) |
| Net loss per share | $(0.74) | $(0.59) | $(1.33) | $(2.44) |
| Operating cash used | Not separately stated | Not separately stated | $(23.4) | $(18.8) |
Gross margin and operating margin are not meaningful because the company had no revenue. For the six months, investing activities provided $21.7 million, largely from investment maturities and sales; financing activities provided $2.1 million, mainly from ATM share sales and option exercises. Cash, cash equivalents and restricted cash ended the period at $48.2 million.
At June 30, 2021, cash and cash equivalents were $48.0 million and short-term investments were $18.7 million, for $66.8 million in cash, cash equivalents and investments. Current assets were $71.4 million and current liabilities $7.0 million. Total liabilities were $7.5 million; the filing reports no borrowings or credit facility. Accumulated deficit was $119.5 million.
Changes versus the prior comparable period
- Q2 operating expenses rose $2.9 million year over year, primarily reflecting higher IMR-687 clinical development and manufacturing costs. Q2 R&D increased $2.2 million; G&A increased $0.7 million.
- Six-month operating expenses increased $5.8 million and net loss increased $6.0 million year over year. R&D rose $3.5 million and G&A rose $2.3 million.
- Six-month operating cash use increased $4.6 million year over year. The year-ago period included substantial IPO and preferred-stock financing proceeds; 2021 financing proceeds were much smaller before the subsequent July offering.
- Common shares outstanding were 17.9 million at June 30, 2021, up from 17.5 million at December 31, 2020. The July offering further increased shares outstanding.
Outlook, management commentary and risks
- Management expected cash, cash equivalents and investments at June 30, together with net proceeds of $46.8 million from a July 16, 2021 public offering, to fund operating expenses and capital requirements through the end of 2022. This is an estimate based on assumptions, and management said additional funding would be needed to support planned activities.
- The July offering sold 8,333,333 shares at $6.00 per share. The reported net proceeds were $46.8 million; the transaction occurred after quarter-end and diluted existing shareholders.
- Ardent, a Phase 2b SCD trial, had completed enrollment. Management expected interim data in Q4 2021, primary-analysis data in Q1 2022 and final analysis in the second half of 2022. In Forte, enrollment was complete in the transfusion-dependent cohort; interim data were expected in Q4 2021, an additional efficacy analysis in Q1 2022 and final analysis in the second half of 2022. These were forward-looking expectations, not reported outcomes.
- Management reported Phase 2a SCD results at the June 2021 EHA Congress: pooled data showed a 40% lower mean annualized vaso-occlusive crisis rate and 38% lower mean annualized VOC-related hospitalization rate versus placebo, plus longer time to first VOC. Biomarker results varied; the filing cautions that early and interim clinical results may change and may not predict later-stage success.
- Open-label extension data were preliminary and based on limited evaluable patients; management reported tolerability and maintained VOC-rate improvement through eight months, alongside variable biomarker changes.
- IMARA had completed preclinical work in heart failure with preserved ejection fraction and was developing a Phase 2 proof-of-concept protocol, with FDA interaction expected in late 2021.
- COVID-19 had caused missed or incomplete visits, delays in the open-label extension, and site activation, enrollment and regulatory-review delays for Ardent and Forte. Further clinical, supply-chain and capital-market disruption remained possible.
- Key risks include dependence on a single clinical-stage candidate, uncertain trial and regulatory outcomes, use of surrogate endpoints that regulators may not accept as clinically meaningful, competition, reliance on third-party manufacturers and CROs, and the need for further financing. IMARA also owed potential Lundbeck milestone payments of up to $23.5 million for licensed compounds, subject to specified achievements.
- The company recognized approximately $0.7 million of employee retention tax credits as an offset to payroll tax expense for the quarter and six-month period. It adopted lease accounting guidance in 2021, recording operating lease right-of-use assets and liabilities; management said the adoption did not materially affect operations.
Most important facts for investors to verify
- Confirm the filing issuer: the supplied document identifies IMARA Inc., not Enliven Therapeutics, Inc.
- Check subsequent filings for actual Ardent and Forte results and whether trial timelines or development plans changed.
- Verify the post-quarter July 2021 offering proceeds, resulting share count and subsequent cash burn against the stated runway through the end of 2022.
- Review the clinical data in full, including trial design, patient counts, endpoint definitions, statistical significance, safety and the limitations of surrogate biomarkers and preliminary analyses.
- Assess future financing requirements, potential dilution, Lundbeck milestone obligations, and risks from COVID-19 and third-party clinical and manufacturing dependencies.